Prognostic signifcance of imaging contrast enhancement for WHO grade II gliomas

Neuro-Oncology

Volumn 11, Issue 2, 2009, Pages 176-182

  Pallud, Johan ^a,f   Capelle, Laurent ^a   Taillandier, Luc ^a,c   Fontaine, Denys ^a,d   Mandonnet, Emmanuel ^a   Guillevin, Rémy ^a   Bauchet, Luc ^a,e   Peruzzi, Philippe ^a,f   Laigle Donadey, Florence ^a   Kujas, Michèle ^a   Guyotat, Jacques ^a,g   Baron, Marie Hélène ^a,h   Mokhtari, Karima ^a,b   Duffau, Hugues ^a,e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c Department of Neuro Oncology   (France)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f REIMS UNIVERSITY HOSPITAL   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Contrast enhancement; Histology; Magnetic resonance imaging; Prognosis; WHO grade II glioma

Indexed keywords

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER MORPHOLOGY; CANCER SURVIVAL; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; GLIOMA; GLIOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PROGNOSIS; WORLD HEALTH ORGANIZATION; ADOLESCENT; BRAIN TUMOR; HEADACHE AND FACIAL PAIN; IMAGE ENHANCEMENT; MIDDLE AGED; NEUROLOGIC DISEASE; SEIZURE; SURVIVAL RATE;

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; GLIOMA; HEADACHE DISORDERS; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PROGNOSIS; SEIZURES; SURVIVAL RATE; YOUNG ADULT;

EID: 65949116152     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-066     Document Type: Article

References (37)

1. Kleihues P, Cavenee W. Tumours of the Nervous System, Pathology and Genetics Classification of Tumours. Lyon, France: International Agency for Research on Cancer Press; 2000.
2. Cavaliere R, Lopes MB, Schiff D. Low-grade gliomas: an update on pathology and therapy. Lancet Neurol. 2005;4:760-770.
3. Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol. 2006;24:1236-1245.
4. Wessels PH, Weber WE, Raven G, et al. Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol. 2003;2:395-403.
5. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53:524-528.
6. Pallud J, Mandonnet E, Duffau H, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organiza- tion grade II gliomas. Ann Neurol. 2006;60:380-383.
7. Mandonnet E, Capelle L, Duffau H. Extension of paralimbic low grade gliomas: toward an anatomical classification based on white matter invasion patterns. J Neurooncol. 2006;78:179-185.
8. Pallud J, Devaux B, Daumas-Duport C, et al. Glioma dissemination along the corticospinal tract. J Neurooncol. 2005;73:239-240.
9. Duffau H. Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plastic- ity. Lancet Neurol. 2005;4:476-486.
10. Brami-Zylberberg F, Grand S, Le Bas JF, Meder JF. [MRI for oligoden- drogliomas]. Neurochirurgie. 2005;51:273-285.
11. Lote K, Egeland T, Hager B, et al. Prognostic significance of CT con- trast enhancement within histological subgroups of intracranial glioma. J Neurooncol. 1998;40:161-170.
12. Daumas-Duport C, Koziak M, Miquel C, et al. [Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies]. Neurochirurgie. 2005;51:247-253.
13. Daumas-Duport C, Tucker ML, Kolles H, et al. Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neurooncol. 1997;34:61-78.
14. Bauman G, Lote K, Larson D, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys. 1999;45:923-929.
15. Kreth FW, Faist M, Grau S, Ostertag CB. Interstitial 125I radiosurgery of supratentorial de novo WHO grade 2 astrocytoma and oligoastro- cytoma in adults: long-term results and prognostic factors. Cancer. 2006;106:1372-1381.
16. Lote K, Egeland T, Hager B, et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol. 1997;15:3129-3140.
17. Lunsford LD, Somaza S, Kondziolka D, Flickinger JC. Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilo- cytic astrocytoma. J Neurosurg. 1995;82:523-529.
18. Nicolato A, Gerosa MA, Fina P, et al. Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients. Surg Neurol. 1995;44:208-221.
19. Philippon JH, Clemenceau SH, Fauchon FH, Foncin JF. Supratentorial low-grade astrocytomas in adults. Neurosurgery. 1993;32:554-559.
20. Piepmeier J, Christopher S, Spencer D, et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocy- tomas. Neurosurgery. 1996;38:872-879.
21. Plathow C, Lichy MP, Bachert P, et al. The role of MRI in patients with astrocytoma WHO II treated with fractionated stereotactic radio- therapy. Eur Radiol. 2004;14:679-685.
22. Plathow C, Schulz-Ertner D, Thilman C, et al. Fractionated stereotac- tic radiotherapy in low-grade astrocytomas: long-term outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 2003;57:996-1003.
23. Walker C, du Plessis DG, Fildes D, et al. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res. 2004;10:7182-7191.
24. Lebrun C, Fontaine D, Ramaioli A, et al. Long-term outcome of oligo- dendrogliomas. Neurology. 2004;62:1783-1787.
25. Grabenbauer GG, Roedel CM, Paulus W, et al. Supratentorial low- grade glioma: results and prognostic factors following postoperative radiotherapy. Strahlenther Onkol. 2000;176:259-264.
26. Schuurman PR, Troost D, Verbeeten B Jr, Bosch DA. 5-year survival and clinical prognostic factors in progressive supratentorial diffuse «low-grade» astrocytoma: a retrospective analysis of 46 cases. Acta Neurochir (Wien). 1997;139:2-7.
27. Vaquero J, Zurita M, Morales C, Coca S. Prognostic significance of tumor-enhancement and angiogenesis in oligodendroglioma. Acta Neurol Scand. 2002;106:19-23.
28. Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997;15:1294-1301.
29. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076-2084.
30. Law M, Oh S, Johnson G, et al. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low- grade gliomas. Neurosurgery. 2006;58:1099-1107.
31. Abdulrauf SI, Edvardsen K, Ho KL, et al. Vascular endothelial growth factor expression and vascular density as prognostic markers of sur- vival in patients with low-grade astrocytoma. J Neurosurg. 1998; 88:513-520.
32. Daumas-Duport C, Varlet P, Tucker ML, et al. Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol. 1997;34:37-59.
33. Hammoud MA, Sawaya R, Shi W, et al. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 1996;27:65-73.
34. Daumas-Duport C, Scheithauer BW, Chodkiewicz JP, et al. Dysem- bryoplastic neuroepithelial tumor: a surgically curable tumor of young patients with intractable partial seizures. Report of thirty-nine cases. Neurosurgery. 1988;23:545-556.
35. Stanescu Cosson R, Varlet P, Beuvon F, et al. Dysembryoplastic neuro- epithelial tumors: CT, MR findings and imaging follow-up: a study of 53 cases. J Neuroradiol. 2001;28:230-240.
36. Finn MA, Blumenthal DT, Salzman KL, Jensen RL. Transient postictal MRI changes in patients with brain tumors may mimic disease pro- gression. Surg Neurol. 2007;67:246-250.
37. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and out- come prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuro- radiol. 2004;25:214-221.